AstraZeneca (AZN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.00
- Estimate
- $1.15
- Surprise
- -12.7%
- Revenue (period 2026-09-30)
- $16.21B
- Score at report (before → after)
- 5.7 → 5.7/10
Revenue source: yfinance_provisional (provisional — SEC XBRL not yet filed for this period).
How the report landed
AstraZeneca (AZN) missed the $1.15 estimate with adjusted EPS of $1.00 — a large 12.7% shortfall. TrendMatrix's engine moved from Buy (Wait) (5.7/10) to Hold at 5.7/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates AZN Sell at 5.8/10.
3 of the last 4 quarters beat the estimate; this quarter's -12.7% surprise compares with a -0.4% four-quarter average. Next scheduled report: 2027-02-09.
What supports the rating
- Sector modifier (Healthcare): +0.8
- Strong earnings beat streak (3/4)
What argues against it
- Thin upside margin: 4.7%
- Negative momentum
- Momentum score 1.9/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $174.35
- Price target
- $182.62
- Stop
- $166.21
- Upside to target
- +4.7%
- Reward-to-risk
- 0.9:1
The stock trades at 24.8× trailing but 15.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 29 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-11-20 — shown for context, not personalized investment advice.
AZN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $272.05B
- P/E (fwd)
- 15.5
- P/E (ttm)
- 24.8
- 52-week range
- $153.41–$212.71
- Off 52-week high
- 18.0%
- RSI (14)
- 29
- Volume vs avg
- 0.71×
- Score today
- 5.8/10